by ASTCT
The following infographics are based on New Developments in CAR T Treatments Webinar Series, which aired on Tuesday, September 10, at 12 p.m. CDT and featured two presentations from Drs....
by Alex Kadhim
The "New Developments in CAR T Treatments" webinar series, held on September 10, 2024, brought together leading experts in the field of cancer immunotherapy to discuss the latest...
by Nature Communications
Researchers say interleukin 4 (IL-4) is implicated in chimeric antigen receptor (CAR) T-cell exhaustion — a primary factor blocking durable response to CAR immunotherapy — and thus may...
by Nature
Adaptor chimeric antigen receptor (AdCAR) T-cell platforms may allow for better immune-targeting of acute myeloid leukemia (AML), according to researchers.
by AACR
Findings from the Phase 3 AURIGA trial support the use of lenalidomide plus daratumumab (D-R) over lenalidomide alone (R) as post-transplant maintenance therapy for patients with newly diagnosed...
by ASTCT Advocacy Update
Mark your calendars for ASTCT's Government Relations Spotlight Session titled "Inside the Administration - Insight into the Federal Government and How We Can Make a Lasting Impact"...